Transcode Therapeutics, Inc. Logo

Transcode Therapeutics, Inc.

Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.

RNAZ | US

Overview

Corporate Details

ISIN(s):
US89357L1052
LEI:
Country:
United States of America
Address:
6 LIBERTY SQUARE, 2109 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Transcode Therapeutics, Inc. is a clinical-stage oncology company focused on developing targeted therapies for metastatic disease. The company's lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b, a key regulator of metastasis. Transcode utilizes its proprietary TTX drug delivery platform, which employs tunable iron oxide nanoparticles to deliver RNA-based therapeutics specifically to cancer cells, addressing a significant challenge in the field. This platform technology has demonstrated broad potential in pre-clinical models across numerous cancer types, including breast, pancreatic, and ovarian cancer. The company aims to eradicate metastatic tumor cells that have spread from the primary tumor. Transcode recently acquired Polynoma LLC to enhance its immuno-oncology and metastatic prevention capabilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Transcode Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Transcode Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Transcode Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany
SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden
STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea
052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan
4888
StemRIM Inc. Logo
Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.
Japan
4599
STENOCARE A/S Logo
Develops and distributes prescription medical cannabis oils in Northern Europe and Australia.
Denmark
STENO
Stoke Therapeutics, Inc. Logo
Developing RNA-based medicines for genetic diseases by increasing protein from the healthy gene.
United States of America
STOK
ST PHARM CO., LTD. Logo
A global CDMO specializing in APIs and RNA therapeutics for the gene therapy market.
South Korea
237690
Structure Therapeutics Inc. Logo
Develops oral small molecule drugs for chronic conditions like metabolic diseases and obesity.
United States of America
GPCR

Talk to a Data Expert

Have a question? We'll get back to you promptly.